CellaVision AB
STO:CEVI

Watchlist Manager
CellaVision AB Logo
CellaVision AB
STO:CEVI
Watchlist
Price: 214.5 SEK
Market Cap: 5.1B SEK
Have any thoughts about
CellaVision AB?
Write Note

Net Margin
CellaVision AB

20.4%
Current
20%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.4%
=
Net Income
150.2m
/
Revenue
737.2m

Net Margin Across Competitors

Country SE
Market Cap 5.1B SEK
Net Margin
20%
Country US
Market Cap 205.2B USD
Net Margin
14%
Country US
Market Cap 193.1B USD
Net Margin
29%
Country US
Market Cap 148.6B USD
Net Margin
16%
Country US
Market Cap 132.9B USD
Net Margin
11%
Country IE
Market Cap 109.9B USD
Net Margin
13%
Country US
Market Cap 64.8B USD
Net Margin
9%
Country DE
Market Cap 56.7B EUR
Net Margin
8%
Country CN
Market Cap 325.5B CNY
Net Margin
33%
Country US
Market Cap 42.2B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

CellaVision AB
Glance View

Market Cap
5.1B SEK
Industry
Health Care

CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

CEVI Intrinsic Value
268.65 SEK
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.4%
=
Net Income
150.2m
/
Revenue
737.2m
What is the Net Margin of CellaVision AB?

Based on CellaVision AB's most recent financial statements, the company has Net Margin of 20.4%.